This article was previously published with some errors. There was a discrepancy between the abstract and the full text regarding the number of patients on continuous hydroxychloroquine therapy over 5 ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

The British Isles Lupus Assessment Group (BILAG)-2004 index is a comprehensive disease activity instrument for systemic lupus erythematosus (SLE). 1 Its key advantages are the ability to capture rare ...

The molecular dissection of the immune system and the identification of druggable targets have played major roles in the biotechnology revolution. In particular, the evolution of therapeutic ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Immune dysregulation in systemic lupus erythematosus (SLE) results in the autoimmune manifestations of SLE, but also leads to an impaired immune response to pathogens and vulnerability to infections ...

A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...

Introduction SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in preparing patients with SLE and ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

Background/ Purpose We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet + double negative 2 (DN2) B cells. Here we investigate the ...

In active SLE, CRP levels are disproportionally low for increased IL-6 levels. While a molecular explanation is lacking, these low CRP levels have been found associated with increased type I ...